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Clinical guidelines are important and influential; they can im-
prove processes involved in patient care, thereby also improv-
ing patient outcomes [1]. They are both commonly
downloaded from journal websites and highly cited [2], help-
ing clinical decision making and service commissioning. Yet,
the quality of such guidelines is highly variable; a review of
279 guidelines published between 1985 and 1997 found that
overall adherence to high-quality methodological standards
was less than 50% [3]. Just as Altman [4] has argued that
the misuse of statistics is unethical for primary research, it is
equally inappropriate for guideline documents to recommend
specific practices unless developed robustly and transparently.
To do otherwise risks erroneous care, and, ultimately, patient
harm. Readers of guidelines (clinicians, patients and policy-
makers) require reassurance that these authoritative docu-
ments have identified, appraised and considered the available
evidence, or draw attention to weaknesses in the literature if
appropriate.
Accordingly, many organisations and professional societies
issuing clinical guidelines have formalised their development
process. This has several advantages, but perhaps most signif-
icantly, it permits methodological rigour to be embedded into
the guideline development process in a consistent fashion. The
organisation is able to stipulate, in advance, minimum stan-
dards for literature searching, evidence synthesis, construction
and ratification of guideline statements; all of which would
otherwise be at the whim of individual guideline development
committees or groups. Yet, what makes a high-quality guide-
line? Fortunately, this question has been the subject of many
years’ work by several organisations, notably the AGREE
consortium, whose most recent iteration (AGREE II) encom-
passes 23 items that can be used to assess the quality of a
particular clinical guideline [5]. As a by-product of this quality
assessment tool, it provides a framework to permit high-
quality guideline development and reporting [6].
The European Society of Gastrointestinal and Abdominal
Radiology (ESGAR) has developed its own guideline devel-
opment process, aiming to standardise and improve the quality
and transparency of guidelines issued under its aegis. This was
initiated in the mid-2017, and guidelines published from
October 2018 onwards will adhere to its structure. The key
components of this process, which adhere to the principles of
AGREE II, are summarised in Fig. 1 and below; the full doc-




Potential topics for guidelines will be sought from the ESGAR
membership, members and leaders of other societies and
members of the public and journal editors. A form is available
on the ESGARwebsite to assist this (at the sameURL as listed
above). Topics will be prioritised based on specific criteria,
namely the burden of the relevant disease (or radiological
technique), the impact that this has on radiological services,
the extent of uncertainty in current clinical practice (including
availability of other high-quality-related guidelines) and the
availability of published evidence upon which a guideline
could be based. The feasibility of developing a guideline using
the resources and expertise of the ESGAR membership will
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also be considered. These criteria will be assessed by the
ESGAR research committee before a new guideline is
commissioned.
Step by step consensus process
Evidence selection and synthesis
The guideline development group will construct and circulate
an initial questionnaire in order to identify the scope and aims
of the guideline, and prioritise topics for detailed literature
review. Thereafter, where possible these topics will be con-
verted into specific clinical questions adopting the PICO for-
mat (patients/participants, intervention, control/comparators,
outcomes). These clinical questions will then serve as the
basis for the literature search. The literature search, including
the databases used, search terms, inclusion dates and language
restrictions, will be documented clearly and used uniformly by
the guideline group. Relevant articles will be retrieved and
summarised into evidence tables with accompanying explan-
atory text, including an assessment of the literature quality.
Consensus statements and committee voting
Using the evidence synthesis tables and explanatory text,
the guideline group will construct draft consensus state-
ments for the final guideline. Where the evidence is con-
tradictory or incomplete, relevant statements can still be
constructed, but may need to be based on the group’s
opinion with anonymous voting, using a modified Delphi
process. Each voting member will be asked regarding their
agreement with a given statement on a five-point scale
(strongly disagree, disagree, neither agree nor disagree,
agree and strongly agree). For a statement to achieve con-
sensus, 80% of guideline group members must agree or
strongly agree with that statement. Statements not achiev-
ing consensus initially may be modified and subjected to
repeat voting; a maximum of three iterations is suggested
as the upper limit before a statement is defined as failing
to reach consensus. Statements that do not achieve con-
sensus may be included in the Discussion of the final
guideline document, but should not be recommended by
the group.
Guideline reporting, appraisal and updating
The final output of the process will be a guideline document,
which will include its background, target audience and en-
dorsing societies. The consensus statements themselves, with
an associated level of evidence quality and strength of recom-
mendation, will be provided, with the evidence summary ta-
bles and explanatory text made available as supplementary
information. Discussion points should include statements that
failed to reach consensus, recommendations for how the
guideline should be implemented in clinical practice, where
the literature review uncovered gaps and opportunities for
further research, and a timeframe for updating the guideline.
During the process of constructing the guideline document,
the group will conduct an internal appraisal of methodological
quality by using the AGREE II instrument and use this to
guide their manuscript preparation. For example, target users
of the guideline must be explicitly identified; statement word-
ing should be clear and unambiguous; and the key recommen-
dations must be easily identifiable. The key aspects of
ESGAR guideline reporting are summarised in Table 1.
Reports will be published in the peer-reviewed literature and
made Open Access, to enhance visibility and likelihood of
implementation.




Well-constructed clinical guidelines have the potential to substan-
tially improve patient care across multiple institutions in different
countries. To maximise their benefit, they must be prioritised,
developed, disseminated and implemented using methodologi-
cally sound and transparent techniques. The ESGAR is commit-
ted to ensuring consistency and excellence in its guidelines, and
all future ESGAR guidance will follow the principles outlined
here.
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Table 1 Key aspects of AGREE II to be incorporated into ESGAR guidelines publications and reports
Item Original AGREE II item
number
Domain 1: scope and purpose
1. The overall objective(s) of the guideline must be specifically described. 1
2. The health question(s) covered by the guideline must be specifically described. 2
3. The population (e.g. patients with a particular condition or undergoing a certain test) to whom the guideline is meant to
apply is specifically described.
3
Domain 2: stakeholder involvementa
4. The guideline development group includes individuals from all the relevant professional groups and subspecialties. 4
5. The target users (e.g. radiologists and gastroenterologists) of the guideline will be clearly defined. 6
Domain 3: rigour of development
6. Systematic methods must be used to search for evidence. 7
7. The criteria for selecting the evidence will be clearly described. 8
8. The strengths and limitations of the body of evidence will be clearly described. 9
9. The methods for formulating the recommendations must be clearly described. 10
10. The health benefits, side effects and risks will be considered in formulating the recommendations. 11
11. There is an explicit link between the recommendations and the supporting evidence. 12
12. All guidelines will be externally reviewed by experts prior to its publication, typically via peer-review and submission
for publication.
13
13. A procedure for updating the guideline will be provided, either in the final guideline publication or via the ESGAR
website.
14
Domain 4: clarity of presentation
14. Recommendations must be specific and unambiguous. 15
15. The different options for management of the condition or health issue will be clearly presented. 16
16. Key recommendations should be easily identifiable and highlighted as such within the final published guideline 17
Domain 5: applicability
17. The guideline should provide advice and/or tools on how the recommendations can be put into practice. 18
18. The guideline should describe facilitators and barriers to its application. 19
19. The potential resource implications of applying the recommendations should be considered. 20
20. The guideline should present monitoring and/or auditing criteria. 21
Domain 6: editorial independence
21. The views of the funding body (i.e. the ESGAR executive) will not be permitted to influence guideline content. 22
22. Competing interests of guideline development group members will be recorded, addressed and published on the
ESGAR website
23
aWhere practicable, patient groups should be consulted during guideline construction (AGREE II item 5)
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